- Patient Education
The FDA has recently approved Vumerity for the treatment of various forms of relapsing-remitting multiple sclerosis. Vumerity works very similarly to Tecfidera, which is another Biogen MS drug. The main difference between these drugs is that Vumerity has been shown to have fewer gastrointestinal side effects than Tecfidera, which usually happens when patients first start the medication. If gastrointestinal side effects have been a problem for you with Tecfidera, Vumerity may be a better solution and you should bring it up with your MS doctor at your next office visit.